President Clinton, Pfizer, and Mylan Announce New Agreements to Lower Prices of Medicines for Patients with Drug-Resistant HIV in Developing Countries
11 August 2009
Pfizer commits to improve access through a 60 percent price decrease to $1 per dose on drug to treat TB in patients taking second-line HIV/AIDS medications. Once-daily four-drug combination for “second-line” treatment of HIV/AIDS available from Matrix, a Mylan company, at $475 annually today and at $425 annually in 2010, 28 percent lower than the current lowest-priced alternative. Combined, the new agreements on HIV and TB -- the leading cause of death of people living with HIV -- reinforce calls for more integrated prevention and treatment of the two diseases.
For more on this story, click on the following web link: New Agreements to Lower Prices of Medicines for Patients with Drug-Resistant HIV in Developing Countries
